Skip to main content

Table 2 Adverse events related to rituximab administration

From: Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature

Timing of rituximab administration

Number of patients who suffered from infusion reactions

Number of patients who had no infusion reactions

Total number of patients

With the first course of chemotherapy

14

15

29

With or after the second course of chemotherapy

4

23

27